Specialty Drug Sales Give Teva Pharmaceutical Industries Ltd. a Boost in Q2 – Motley Fool


Motley Fool
Specialty Drug Sales Give Teva Pharmaceutical Industries Ltd. a Boost in Q2
Motley Fool
It hasn’t been the greatest year so far for Teva Pharmaceutical Industries (NYSE:TEVA) shareholders. The drugmaker’s stock is down over 18% year to date and has been stuck at that level or lower for the past three months. Teva announced its second
Teva Inks Biggest Deal in Israeli Pharmaceutical Industry’s HistoryAlgemeiner
Actavis Generics acquired by Teva Pharmaceutical IndustriesMaltaToday
Teva Pharmaceutical Industries Limited Q2 Profit Declines 6%Nasdaq
Legal News Line -BBNS -Market Exclusive
all 152 news articles >>

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd